Treatment of insulin resistance associated with prolonged physical inactivity

A technique for insulin resistance, physical activity, applied in the field of biomarkers, to address issues such as poor quality of life outcomes

Inactive Publication Date: 2015-12-23
ABBOTT LAB INC
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These adverse metabolic changes can lead to poor quality of life outcomes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of insulin resistance associated with prolonged physical inactivity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0126] Example 1: Effect of HMB intervention on circulating levels of IGFBP-2 in subjects who have undergone 10 days of bed rest.

[0127] IGF-binding proteins prolong the half-life of IGF and alter the interaction of IGF with their cell surface receptors. Reduction of circulating IGFBP-2 is associated with increased insulin resistance in human subjects.

[0128] As shown in Table 1, there was a mean decrease of -30.54 ng / ml or -24.56% decrease in circulating levels of IGFBP-2 in 8 control subjects after 10 days of bed rest. In contrast, the average decrease in IGFBP-2 levels in blood from 10 subjects treated with HMB was much less. As shown in Table 1, there was a mean decrease of -20.89 ng / ml or -15.63% decrease in blood levels of IGFBP-2 in these HMB-treated subjects. These results indicate that HMB attenuates or attenuates the decrease in blood levels of IGFBP-2 that occurs during prolonged bed rest in control subjects.

Embodiment 2

[0129] Example 2: Effect of HMB intervention on circulating levels of C-peptide in subjects who have undergone 10 days of bed rest.

[0130] The beta cells of the pancreas produce C-peptide (Swiss-Prot accession number: P01308) as part of the proinsulin molecule (insulin precursor). Increases in circulating C-peptide are associated with insulin resistance in human subjects.

[0131] As shown in Table 1, there was a mean increase in circulating levels of C-peptide of 0.54 ng / ml or a mean increase of 43.0% in 8 control subjects after 10 days of bed rest. In contrast, the average increase in C-peptide levels in blood from the 10 HMB-treated subjects was much greater. As shown in Table 1, there was a mean increase of 0.28 ng / ml or a 29.59% increase in blood levels of C-peptide in these HMB-treated subjects after 10 days of bed rest. These results indicate that HMB attenuates or attenuates the increase in blood levels of C-peptide that occurs during prolonged bed rest in untrea...

Embodiment 3

[0132] Example 3: Effect of HMB intervention on circulating levels of leptin in subjects who have undergone 10 days of bed rest.

[0133] Leptin is a 16-kDa adipocyte-derived hormone that circulates in serum in both free and bound forms (MantzorosCS, Ann Intern Med 1999;130:671-680). Studies have demonstrated that insulin resistance is associated with elevated plasma leptin levels independent of body fat mass (Segal KR, et al., Diabetes 1996;45:988-991.).

[0134]As shown in Table 1, there was a mean increase in circulating levels of leptin of 5.06 ng / ml in 8 control subjects after 10 days of bed rest. In contrast, there was a lower mean increase in leptin circulating levels of 4.11 ng / ml in the 10 HMB-treated subjects after 10 days of bed rest. These values ​​were significantly lower than control values. These results indicate that HMB attenuates or attenuates the increase in blood levels of leptin that occurs during prolonged bed rest in untreated control subjects. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor- Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 61 / 783,301, filed March 14, 2013, U.S. Provisional Application No. 61 / 840,990, filed June 28, 2013, and U.S. Provisional Application No. 61 / 866,061, filed August 15, 2013 priority and any rights and interests, the entire contents of which are incorporated herein by reference. technical field [0003] The present disclosure relates to biomarkers. More specifically, the present disclosure relates to insulin resistance biomarkers whose levels in blood vary during prolonged or chronic periods of physical inactivity and methods of using these biomarkers. The present disclosure also relates to methods of reducing or attenuating insulin resistance associated with chronic physical inactivity in a human subject. Background technique [0004] In different circumstances, adults are asked to undergo prolonged bed rest. For example, adults who are hospitalized due to illn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/19A61P3/10
CPCA61K31/19A61P3/10A61P43/00G01N33/6893G01N2333/47G01N2333/4704G01N2333/575G01N2800/52
Inventor M.罗S.佩雷拉N.埃登斯G.戴维斯S.贾维尔R.钱德兰
Owner ABBOTT LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap